Compare · EYPT vs RVTY
EYPT vs RVTY
Side-by-side comparison of EyePoint Inc. (EYPT) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EYPT and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $12.32B, about 12.1x EYPT ($1.02B).
- EYPT has been more active in the news (7 items in the past 4 weeks vs 4 for RVTY).
- RVTY has more recent analyst coverage (20 ratings vs 11 for EYPT).
- Company
- EyePoint Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $1.02B
- $12.32B
- 1M return
- -15.50%
- -
- 1Y return
- +16.22%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 4
- Recent ratings
- 11
- 20
EyePoint Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Latest EYPT
- EyePoint Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Stifel initiated coverage on EyePoint with a new price target
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- President and CEO Duker Jay S. converted options into 16,667 shares and covered exercise/tax liability with 8,059 shares, increasing direct ownership by 873% to 9,594 units (SEC Form 4) (for withholding tax)
- EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
- Cantor Fitzgerald resumed coverage on EyePoint with a new price target
- Chief Medical Officer Ribeiro Ramiro sold $73,167 worth of shares (4,875 units at $15.01) and exercised 4,875 shares at a strike of $8.26 (SEC Form 4)
- EyePoint Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Chief Financial Officer Elston George converted options into 7,500 shares and covered exercise/tax liability with 3,627 shares, increasing direct ownership by 4% to 91,691 units (SEC Form 4) (withholding obligation)
Latest RVTY
- Vice President and CAO Gonzales Anita sold $9,306 worth of shares (85 units at $109.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,201 units (SEC Form 4)
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026
- Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
- Bernstein resumed coverage on Revvity with a new price target
- SEC Form 11-K filed by Revvity Inc.
- Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
- Vice President and CAO Gonzales Anita covered exercise/tax liability with 33 shares, decreasing direct ownership by 0.45% to 7,286 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.